ImmunityBio Inc (NASDAQ:IBRX) shares rose 8.6% in premarket trading Wednesday after the company announced the FDA accepted its supplemental Biologics License Application for ANKTIVA in combination ...
ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated commercial-stage immunotherapy company, today announced results ...
ImmunityBio (IBRX) stock jumps as the FDA agrees to review the company's bid to expand the label for bladder cancer therapy ...
Supplemental BLA seeks to expand the ANKTIVA label to include patients with BCG-unresponsive NMIBC with papillary diseaseFDA ...
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that ...
Ferring Pharmaceuticals today announced a new real-world case series demonstrating that re-induction with ADSTILADRIN® (nadofaragene firadenovec-vncg) resulted in complete responses (CR) in ...
TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-month landmark and 55% complete response ...
ImmunityBio Inc. IBRX presented two indirect treatment comparison analyses, highlighting efficacy and safety outcomes for ...
IBRX secures five U.S. patents for Anktiva in bladder cancer, extending franchise protection through 2035 amid strong sales ...
Researchers have found in a retrospective cohort study of patients with non–muscle-invasive bladder cancer (NMIBC) treated ...
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of two Photocure-supported abstracts at the ...
Dr. Elisa Port draws on patient stories like Martin's and Evert's and 25 years of experience for a new book on breast care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results